DSM-Firmenich Past Earnings Performance
Past criteria checks 0/6
DSM-Firmenich's earnings have been declining at an average annual rate of -40.9%, while the Chemicals industry saw earnings declining at 3.8% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-40.9%
Earnings growth rate
-38.7%
EPS growth rate
| Chemicals Industry Growth | 4.3% |
| Revenue growth rate | 6.5% |
| Return on equity | -0.8% |
| Net Margin | -1.5% |
| Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DSM-Firmenich makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 12,455 | -190 | 2,535 | 652 |
| 31 Mar 24 | 11,541 | -424 | 2,535 | 652 |
| 31 Dec 23 | 10,627 | -658 | 2,535 | 652 |
| 30 Sep 23 | 9,686 | -456 | 1,772 | 295 |
| 30 Jun 23 | 8,745 | -254 | 1,772 | 295 |
| 31 Mar 23 | 8,568 | 100 | 1,772 | 295 |
| 31 Dec 22 | 8,390 | 454 | 1,772 | 295 |
| 30 Sep 22 | 9,582 | 837 | 895 | 162 |
| 30 Jun 22 | 7,867 | 823 | 1,649 | 274 |
| 31 Mar 22 | 7,568 | 822 | 1,649 | 274 |
| 31 Dec 21 | 7,269 | 820 | 1,649 | 274 |
| 30 Sep 21 | 7,955 | 660 | 2,517 | 560 |
| 30 Jun 21 | 7,558 | 493 | 1,622 | 398 |
| 31 Mar 21 | 7,572 | 423 | 1,622 | 398 |
| 31 Dec 20 | 8,106 | 448 | 1,622 | 398 |
| 30 Sep 20 | 7,960 | 510 | 1,639 | 295 |
| 30 Jun 20 | 8,034 | 557 | 1,639 | 295 |
| 31 Mar 20 | 9,011 | 722 | 1,795 | 349 |
| 31 Dec 19 | 7,998 | 675 | 1,639 | 295 |
| 30 Sep 19 | 8,272 | 820 | 1,839 | 348 |
| 30 Jun 19 | 8,502 | 794 | 1,839 | 348 |
| 31 Mar 19 | 9,124 | 934 | 1,839 | 348 |
| 31 Dec 18 | 9,267 | 1,069 | 1,839 | 348 |
| 30 Sep 18 | 9,235 | 984 | 1,753 | 334 |
| 30 Jun 18 | 9,106 | 2,082 | 1,753 | 334 |
| 31 Mar 18 | 8,908 | 1,942 | 1,753 | 334 |
| 31 Dec 17 | 8,632 | 1,761 | 1,753 | 334 |
| 30 Sep 17 | 8,471 | 1,676 | 1,694 | 309 |
| 30 Jun 17 | 8,333 | 738 | 1,694 | 309 |
| 31 Mar 17 | 8,166 | 711 | 1,694 | 309 |
| 31 Dec 16 | 7,920 | 645 | 1,694 | 309 |
| 30 Sep 16 | 7,831 | 588 | 1,605 | 332 |
| 30 Jun 16 | 7,778 | 274 | 1,605 | 332 |
| 31 Mar 16 | 7,749 | 214 | 1,605 | 332 |
| 31 Dec 15 | 7,722 | 174 | 1,605 | 332 |
| 30 Sep 15 | 7,607 | 66 | 1,382 | 304 |
| 30 Jun 15 | 7,456 | 114 | 1,382 | 304 |
| 31 Mar 15 | 7,245 | 115 | 1,382 | 304 |
| 31 Dec 14 | 7,051 | 123 | 1,382 | 304 |
| 30 Sep 14 | 7,415 | 112 | 1,430 | 340 |
| 30 Jun 14 | 7,834 | 138 | 1,430 | 340 |
| 31 Mar 14 | 8,362 | 182 | 1,430 | 340 |
| 31 Dec 13 | 8,858 | 252 | 1,430 | 340 |
Quality Earnings: DSFIRA is currently unprofitable.
Growing Profit Margin: DSFIRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSFIRA is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.
Accelerating Growth: Unable to compare DSFIRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DSFIRA is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-36.8%).
Return on Equity
High ROE: DSFIRA has a negative Return on Equity (-0.78%), as it is currently unprofitable.